Clinical trial NCT06602674: PET/CT-Based Image Analysis and Machine Learning of Hypermetabolic Pulmonary Lesions
Official title: PET/CT Imaging-Based Distinction of Pulmonary Lymphoma and Other Hypermetabolic Lesions Via Imaging Manifestations and Machine Learning Techniques: a Multicenter Retrospective Study
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Lung Cancers
Pulmonary Lymphomas
Pulmonary Metastases
Benign Pulmonary Diseases
Keywords: positron emission tomography/computed tomography
pulmonary lymphoma
lung cancer
deep learning
radiomics
Lead sponsor: Ruijin Hospital
Sponsor class: OTHER
Collaborators: name: Shanghai Pulmonary Hospital, Shanghai, China
name: Jiangsu Province Hospital of Traditional Chinese Medicine
name: Ruijin North Hospital
name: Luan people&#39;s hospital
First posted: 2024-09-19
Enrollment: 600
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This retrospective study enrolled patients who underwent PET/CT exams at the Nuclear Medicine Department from January 2015 to Feburary 2024 in 5 institutions: Ruijin Hospital, Proton Center of Ruijin North Hospital, Shanghai Pulmonary Hospital, Lu\&amp;amp;#39;an People\&amp;amp;#39;s Hospital of Anhui Province and the Affiliated Hospital of Nanjing University of Traditional Chinese Medicine.

Brief summary: First, we analyse the types, imaging findings and relevant treatment responses based on PET/CT to complete a more comprehensive view of pulmonary lymphomas.

Then, some models based on radiomics features will be developed to verify the possibility of differentiating pulmonary lymphomas via machine learning and develop a multi-class classification model.

The final objective of this study is to develop a set of deep learning models for preliminary lung lesion segmentation and multi-class classification. The models will classify FDG-avid lung lesions into four groups, each defined by their pathological origin, primary therapy and relevant clinical department.

Detailed description: 1. The local image feature extraction software (LIFEx, v 7.4.0, France) was employed for the image review and measurement of relevant data. Three observers independently interpreted the images. In cases of disagreement, the opinion of a senior doctor with over a decade of experience was given precedence. The imaging findings were recorded based on the baseline examinations. Lesion counts, locations, and descriptive labels were systematically logged in accordance with the norms set out in imaging report. The statistical software SPSS (v26.0) was used in data sorting and calculation. Chi-square test was employed to compare SPL and PPL based on categorical variables like CT findings, while T-test was used to assess continuous variables like glycemia and SUV. Given the predominance of categorical variables, chi-square, or Fisher\&#39;s exact test (for samples \&lt;40 or \&gt;20% cells with \&lt;5 expected counts) was utilised to assess treatment response and imaging performance. Spearman\&#39;s correlation coefficient was employed to analyse the relationship between categorical and SUV-based continuous variables.
2. In this study, the metabolic tumor volume at a relative threshold of 40% (MTV40%) was selected as the volume of interest (VOI) for image analysis. For feature extraction, we employed the Python (v3.11.7)-based radiomics feature extraction toolkit PyRadiomics (v3.1.0), along with the medical image processing library SimpleITK (v2.3.1), the numerical computation and data manipulation library Numpy (v1.26.2), and the wavelet transform library PyWavelet (v1.5.0). Feature selection was conducted using RStudio (v.2023.12.0+369) based on the R programming language (v4.2.0). To ensure computational efficiency and avoid overfitting, the number of features retained was limited to 10% or less of the number of lesions in the training set. Model analysis and validation were primarily performed using RStudio as well.
3. The deep learning study divides the task of identifying and classifying hypermetabolic lung lesions into two stages: segmentation and classification. In the segmentation stage, we first utilized the open-source 2D model Lungmask to automatically crop the lung region from whole-body PET/CT images, ensuring that subsequent processing is focused on the lung area. Next, we developed a 3D UNet model with residual modules specifically designed for segmenting hypermetabolic lung lesions. This model takes the cropped PET/CT images as input, efficiently extracting lesion information from the three-dimensional images and accurately segmenting the hypermetabolic lung lesion areas.The model was then applied to both internal test sets and external validation sets for inference, resulting in the extraction of lesion-containing ROIs.

Eligibility criteria: Inclusion criteria:

1. Adult patients (≥18 years);
2. Primary or recurrent lymphoma, ≥6 months from last treatment; primary lung cancer patients without prior malignancy;
3. Benign solid lung lesions, without prior malignancy;
4. Pulmonary metastasis, untreated with lung radiotherapy or particle implantation;
5. Baseline assessment revealing PET-positive pulmonary lesions.
6. Pathological results within 3 months of exam date, confirmed lung lesion types via tracheoscopy, lung puncture, or surgery.
7. Baseline pulmonary lesions remaining considered to be pulmonary lymphoma (or metastases) based on follow-up clinical and imaging evaluation.

Exclusion criteria:

1. Poor image quality;
2. Inability to delineate the boundaries of lung lesions on CT images;
3. Artifacts caused by nearby devices such as stents or drainage tubes.

Primary outcomes:
measure: Imaging/radiomics/deep learning features of 18F-FDG PET/CT image
timeFrame: Baseline
Secondary outcomes:
measure: Efficiency of the segmentation model
timeFrame: immediately after the development and testing of models
measure: Efficiency of the classification model
timeFrame: immediately after the development and testing of models
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine
state: Shanghai
Study officials:
References: